

Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)

NCT07268222

Status	RECRUITING
Phase	Phase 4
Sponsor	Laikon General Hospital, Athens
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (2)

- Adults \geq 18 years old with MACS and unilateral or bilateral adrenal adenomas or hyperplasia (based on imaging)
- mg overnight dexamethasone suppression test (ODST): Cortisol levels at 8.00 am $>1.8 \mu\text{g/dl}$ AND i) ACTH $< 15 \text{ pg/ml}$ OR ii) abnormal midnight salivary cortisol OR iii) Urinary free cortisol levels (UFC) /24h e of the UNL

Exclusion (5)

- Abnormal liver enzymes
- eGFR $< 40 \text{ ml/min/1.73 m}^2$
- Pseudocushing syndrome
- Patients with any malignancy (active or past history), including ACC
- ACTH-dependent Cushing syndrome (Cushing disease or ectopic Cushing syndrome)

Locations (1 total)

Laikon General Hospital, Athens, Greece